To design a rational PARPi combination therapy, we screened a library of FDA-approved drugs and identified the mutant IDH1 inhibitor ivosidenib, which greatly potentiates PARPi efficacy in either BRCA1/2 wild-type (WT) or mutant cancer cells. This evidence concerns the gene IDH1 and cancer.